Samabriva, a plant-based biotechnology company, completed a Series-A round of financing to secure an investment of nearly €4 million. Its plant-based bioproduction process has the potential to transform production of high value molecules – such as natural active molecules (secondary metabolites) and recombinant proteins – for the pharmaceutical and cosmetic sectors.

The immediate focus will be on the production of active pharmaceutical ingredients (API) using confined and controlled plant-based expression systems.

According to the company, with lead investors like Noshaq and Investsud Tech now on board, this financing round will accelerate Samabriva’s growth. The company will be able to develop its first industrial production site in the Liège region of Belgium, taking advantage of the exceptional biotech ecosystem there, while maintaining the research center in France.

The funding will also increase the speed with which Samabriva’s technology is deployed and ensure the transformation of the company into a CDMO.

Marina Guillet, CEO of Samabriva said, “We’re delighted that leading biotech investors have seen the incredible potential of Samabriva. With their support for our expansion in the rapidly growing API market, we’ll be ideally placed to meet the needs of the pharmaceutical sector.”